Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

295.09 +5.19 (+1.79%)
Streaming Delayed Price Updated: 3:53 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
47 48 Next >
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
Via Benzinga
FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal
The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ: AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC... 
Via Benzinga
Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle
The FTC is pulling back somewhat on its effort to challenge the deal. 
Via Investor's Business Daily
4 Surefire Stocks to Buy in the Next Bear Market
Not all companies struggle when economic weakness takes hold. 
Via The Motley Fool
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that... 
Via Benzinga
This Is What Whales Are Betting On Amgen
Via Benzinga
Peering Into Amgen's Recent Short Interest
Via Benzinga
Is Amgen Stock a Top Buy and Hold?
The biotech checks several important boxes for long-term shareholders. 
Via The Motley Fool
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. 
Via InvestorPlace
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
Could Amgen Stock Help You Become a Millionaire?
Its pending acquisition of Horizon Therapeutics could make the company much bigger. 
Via The Motley Fool
Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
The Latest Analyst Ratings for Amgen
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
Want Rising Dividend Income? Buy Amgen Stock
The drugmaker possesses a solid medicine portfolio and pipeline. 
Via The Motley Fool
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
QUALCOMM, AIG And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Nasdaq Suffers Second Straight Week of Losses, Breaks Key Support Level As Tech Bears Return: Is This Time Different?
Via Benzinga
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come. 
Via MarketBeat
Topics Bankruptcy Economy
Exposures Economy Financial Legal
The 3 Best Biotech Stocks to Buy in August
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Amgen Inc. (NASDAQ: AMGN) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Via Benzinga
1 Top Dividend Growth Stock to Buy on the Dip
Investors' patience will be rewarded. 
Via The Motley Fool
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
By David Willey, Benzinga 
Via TheNewswire.com
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. 
Via Benzinga
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.